Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05536739 · ClinicalTrials.gov registry record · NA

Adaptive Hip Exoskeleton for Stroke Gait Enhancement

A NA study of Stroke, sponsored by Georgia Institute of Technology.

Recruiting
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT05536739 is a NA study of Stroke that is actively recruiting participants, run by Georgia Institute of Technology. The registered enrollment target is 12 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05536739, a NA study of Stroke, is actively recruiting participants, sponsored by Georgia Institute of Technology.

RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This work will focus on new algorithms for robotic exoskeletons and testing these in human subject tests. Individuals who have previously had a stroke will walk while wearing a robotic exoskeleton on a specialized treadmill as well as during other movement tasks (e.g. over ground, stairs, ramps). The study will compare the performance of the advanced algorithm with not using the device to determine the clinical benefit.

Conditions Studied

Interventions

  • DEVICE Robotic hip exoskeleton
  • OTHER No hip exoskeleton
  • DEVICE Unpowered hip exoskeleton

Study Locations (1)

Georgia

  • Exoskeleton and Prosthetic Intelligent Controls Lab - Atlanta

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2025-05-21
Est. Completion 2027-07-31
Phase NA

Sponsor

Georgia Institute of Technology

24 total trials

What the Registry Record Tells You About NCT05536739

The ClinicalTrials.gov registry entry for NCT05536739 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The listed sponsor is Georgia Institute of Technology, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 3 interventions - of which Robotic hip exoskeleton is the first listed.

NCT05536739 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT05536739 about?

NCT05536739 is a clinical study titled "Adaptive Hip Exoskeleton for Stroke Gait Enhancement". This work will focus on new algorithms for robotic exoskeletons and testing these in human subject tests. Individuals who have previously had a stroke will walk while wearing a robotic exoskeleton on a specialized treadmill as well as during other movement tasks (e.g. over ground, stairs, ramps). Th...

What is the current status of trial NCT05536739?

This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2025-05-21. Estimated completion is 2027-07-31.

What conditions does trial NCT05536739 study?

This clinical trial studies the following conditions: Stroke.

What interventions are being tested in trial NCT05536739?

The interventions under investigation include: Robotic hip exoskeleton (DEVICE), No hip exoskeleton (OTHER), Unpowered hip exoskeleton (DEVICE).

Who is sponsoring clinical trial NCT05536739?

This trial is sponsored by Georgia Institute of Technology, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05536739 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.